MSKCC relies on the counsel of outside advisors, represented by its Board of Scientific Consultants (BSC), the guidance of its Board of Overseers and Managers, as well as many internal planning processes to support the planning and evaluation of the research programs and core facilities at the Center. MSKCC has used the guidance it has received to develop and execute its initiatives for research and clinical expansion. During the past five years, the BSC has reviewed the research in many areas, including the Developmental and Stem Cell Biology Program, the Molecular Structure Program, the Prevention, Control and Population Research Program (now the Survivorship, Outcomes, and Risk Program), along with its efforts in Immigrant Health and Cancer Disparities, the Immunology and Transplantation Program, the Imaging and Radiation Sciences Program, the Cancer Biology and Experimental Pathology Program, Experimental Therapeutics, and disease-specific components of the Clinical Research Program. The BSC has also reviewed some of the newly recruited junior investigators and the training programs that bring outstanding students to train in MSKCC's laboratories. In addition to the BSC, the senior leaders receive strategic counsel from the MSKCC Board of Overseers and Managers to provide both community and financial stewardship as well as tactical advice on Center policies. A Task Force was also created to internally evaluate the Cores' infrastructure, and several improvements have been enacted. Through input from program members and the Associate Directors, further collaborative research centers that foster interactions between laboratory and clinical investigators have also been established. The recommendations made by the BSC and other planning groups have led to program reorganizations, new faculty recruitments, shared resource development, and facility expansions.

Public Health Relevance

MSKCC's planning and evaluation processes provide external and internal counsel for its research programs. The expert advice that it receives guides the development of its strategic initiatives so that it can best meet the mission of an NCI-designated Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-51
Application #
9204754
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
51
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Davis, Mellar P; Pasternak, Gavril; Behm, Bertrand (2018) Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. Drugs 78:1211-1228
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Horvat, Joao V; Durando, Manuela; Milans, Soledad et al. (2018) Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis. Eur Radiol 28:2516-2524
Al Efishat, Mohammad A; Attiyeh, Marc A; Eaton, Anne A et al. (2018) Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg 268:340-347
Dickson, Brendan C; Sung, Yun-Shao; Rosenblum, Marc K et al. (2018) NUTM1 Gene Fusions Characterize a Subset of Undifferentiated Soft Tissue and Visceral Tumors. Am J Surg Pathol 42:636-645
Gao, Yiming; Quinn, Brian; Pandit-Taskar, Neeta et al. (2018) Patient-specific organ and effective dose estimates in pediatric oncology computed tomography. Phys Med 45:146-155
Yang, Lin; Alyasova, Anna; Ye, Dingwei et al. (2018) RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. BMC Cancer 18:195
Majumdar, Susruta; Devi, Lakshmi A (2018) Strategy for making safer opioids bolstered. Nature 553:286-288
Freites-Martinez, Azael; Shapiro, Jerry; van den Hurk, Corina et al. (2018) CME Part 2: Hair disorders in cancer survivors Persistent chemotherapy-induced alopecia, persistent radiotherapy-induced alopecia, and hair growth disorders related to endocrine therapy or cancer surgery. J Am Acad Dermatol :
Barbetta, Arianna; Nobel, Tamar B; Sihag, Smita et al. (2018) Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. Ann Thorac Surg 106:864-871

Showing the most recent 10 out of 8799 publications